Role of lipoprotein lipase in triglyceride metabolism: Potential therapeutic target

Future Lipidology

Volumn 3, Issue 4, 2008, Pages 385-397

  Franssen, Remco ^a   Visser, Maartje E ^a   Kuivenhoven, Jan Albert ^a   Kastelein, John J P ^a   Dallinga Thie, Geesje M ^a   Stroes, Erik S G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Lipoprotein; Lipoprotein deficiency; Primary hypertriglyceridemia; Therapy; Triglycerides

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 (4 BROMO 2 CYANOPHENYLCARBAMOYL)BENZYLPHOSPHONIC ACID DIETHYL ESTER; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDIUM CHAIN TRIACYLGLYCEROL; MIPOMERSEN; N 1886; OMEGA 3 FATTY ACID; PARVOVIRUS VECTOR; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; GENE THERAPY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SUBSTITUTION THERAPY;

EID: 48749100753     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.4.385     Document Type: Review

References (108)

1. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analyiis ofpopulation-based prospective studies. J. Cardiovasc. Risk 3(2),213-219 (1996).
2. Krauss RM: Atherogenicity of triglyceriderich lipoproteins. Am. J. Cardiol. 81(4A), 13B-17B (1998).
3. Fortson MR, Freedman SN, Webster PD III, Clinical assessment of hyperlipidemic pancreatitis. Am. J. Gastroenterol. 90(12), 2134-2139 (1995).
4. Austin MA, King MC, Vranizan W, Krauss RM: Artherogenis lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2), 495-506 (1990).
5. Campos H, Genest JJ Jr, Blijlevens E et al.: Low density lipoprotein particle size and coronary artery disease. Arterioscler. Thromb. 12(2), 187-195 (1992).
6. Superko RH: Lipoprotein subclasses and atherosclerosis. Front. Biosci. 6, D355-D365 (2001).
7. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298(3), 309-316 (2007).
8. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298(3), 299-308(2007).
9. Sarwar N, Danesh J, Eiriksdottir G et al.: Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (4), 450-458 (2007).
10. Ridker PM: Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin. Chem. 54(1), 11-13 (2008).
11. Warnick GR, Nakajima K. Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clin. Chem. 54(1), 14-16 (2008).
12. Havel RJ, Hamilton RL. Hepatic catabolism of remnant lipoproteins: where the action is. Arterioscler. Thromb. Vasc. Biol. 24(2), 213-215 (2004).
13. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS: Remnant lipoproteins and atherosclerosis. Curr. Atheroscler. Rep. 7(2), 140-147 (2005).
14. Yokoyama M, Seo, T, Park T et al.: Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J. Lipid Res. 48(3), 646-655 (2007).
15. Zechner R, Strauss JG, Haemmerle G, Lass A, Zimmermann R: Lipolysis: pathway under construction. Curr. Opin. Lipidol. 16(3), 333-340 (2005).
16. Borggreve SE, de Vries R, Dullaart RP: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and Type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer protein. Eur. J. Clin. Invrst. 33(12), 1051-1069 (2003).
17. Dallinga-Thie G M, Dullaart RP, van Tot A: Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in Type 2 diabetes: effects of apolipoproteins. Curr. Opin. Lipidol. 18(3), 251 257 (2007).
18. Merkel M, Eckel RH, Goldberg IJ: Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43(12), 1997-2006 (2002).
19. Mahley RW, Huang Y: Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J. Clin. Invest. 117(l), 94-98 (2007).
20. MacArthur JM, Bishop JR, Stanford IG et al.: Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117(1), 153-164 (2007).
21. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446(7139), 1030-1037(2007).
22. Hahn PF: Abolishment of alimentary lipemia following injection of heparin. Science 98(2531), 19-20 (1943).
23. Korn ED: Clearing factor, a heparin-activated lipoprorcin lipase. II. Substrate specificity and activation of coconut oil. J. Biol Chem. 215(1), 15-26 (1955).
24. Choi SY, Hirata K, Ishida T, Querrermous T, Cooper AD: Endothelial lipase: a new lipase on the block. J. Lipid Res. 43(11), 1763-1769 (2002).
25. Weinstock PH, Bisgaier CL, Aalto-Setala K et al.: Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96(6), 2555-2568 (1995).
26. Bensadoun A: Lipoprotein lipase. Annu. Rev. Nutr. 11, 217-23 7 (1991).
27. Ge H, Cha JY, Gopal H et al.: Differential regulation and properties of angiopoietin-like proteins 3 and 4. J. Lipid Res. 46(7), 1484-1490 (2005).
28. Peterfy M, Ben-Zeev O, Mao HZ et al.: Mutations in LMF1 Cause combined lipase deficiency and severe hypertriglyceridemia. Nat. Genet. 39(12), 1483-1487 (2007).
29. Reue K, Doolittle MH: Naturally occurring mutations in mice affecting lipid transport and metabolism. J. Lipid Res. 37(7), 1387-1405 (1996).
30. Davis RC, Ben-Zeev O, Martin D, Doolittle MH: Combined lipase deficiency in the mouse. Evidence of impaired lipase processing and secretion. J. Mol. Chem. 265(29), 17960-17966 (1990).
31. Olivecrona G, Beisiegel U: Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler. Thromb. Vasc. Biol. 17(8), 1545-1549 (1997).
32. Lookene A, Zhang L, Hultin M, Olivecrona G: Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer. J. Biol. Chem. 279(48), 49964-49972 (2004).
33. Shachter NS: Apolipoproteips C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12(3), 297-304 (2001).
34. Schaap FG, Rensen PC, Voshol PJ et al.: ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279(27), 27941-27947 (2004).
35. Sukonina V, Lookene A, Olivecrona T, Olivecrona G: Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl Acad. Sci. USA 103(46), 17450-17455 (2006).
36. Dallinga-Thie GM, van Tol A, Hattori H, van Vark-van der Zee LC, Jansen H, Sijbrands EJ: Plasma apolipoprotein A5 and triglycerides in Type 2 diabetes. Diabetologia 49(7), 1505-1511 (2006).
37. Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR: The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in Type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care 30(8), 2083-2085 (2007).
38. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Frucharr JC, Wang CS: Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33(7), 995-1003 (1992).
39. Merkel M, Loeffler B, Kluger M et al.: Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280(22), 21553-21560 (2005).
40. Young SG, Davies BS, Fong LG et al.: GPIHBPl: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr. Opin. Lipidol. 18(4), 389-396 (2007).
41. Beigneux AP, Davies BS, Gin P et al.: Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 5(4), 279-291 (2007).
42. Wang J, Cao H, Ban MR et al.: Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler. Thromb. Vasc. Biol. 27(11), 2450-2455 (2007).
43. Murthy V, Julien P, Gagne C: Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol. Ther. 70(2), 101-135 (1996).
44. Mero N, Suurinkeroinen L, Syvanne M, Knudsen P, Yki-Jarvinen H, Taskinen MR: Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant. J. Lipid Res. 40(9), 1663-1670 (1999).
45. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 99(22), 2901-2907 (1999).
46. Kastelein JJ, Ordovas JM, Wittekoek ME et al.: Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin. Genet. 56(4), 297-305 (1999).
47. Hokanson JE: Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int. J. Clin. Lab. Res. 27(1), 24-34 (1997).
48. Van Bockxmeer FM, Lin Q, Mamotte C, Burke V, Taylor R: Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 157(1), 123-129 (2001).
49. Wittekoek ME, Pimstone SN, Reymer PW et al.: A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 97(8), 729-735 (1998).
50. Wittekock ME, Moll E, Pimstone SN et al.: A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 19(11), 2708-2713 (1999).
51. Hokanson JE: Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr. Opin. Lipidol. 10(5), 393-399 (1999).
52. Kastelein JJ, Groenemeyer BE, Hallman DM et al.: The Asn9 variant of lipoprotein lipase is associated with the 93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. Clin. Genet. 53(1), 27-33 (1998).
53. Frikke-Schmidt R, Sing CF, Nordestgaard BG, Steffensen R, Tybjaerg-Hansen A: Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Hum. Genet. 120(6), 865-877 (2007).
54. Gagne SE, Larson MG, Pimstone SN et al.: A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin. Genet. 55(6), 450-454 (1999).
55. Henderson HE, Kastelein JJ, Zwinderman AH et al.: Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J. Lipid Res. 40(4), 735-743 (1999).
56. Jemaa R, Fumeron F, Poirier O et al.: Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l'Infarctus du Myocarde. J. Lipid Res. 36(10), 2141-2146 (1995).
57. Myllykangas L, Polvikoski T, Sulkava R et al.: Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann. Med. 33(7), 486-492 (2001).
58. Shimo-Nakanishi Y, Urabe T, Hattori N et al.: Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 32(7), 1481-1486 (2001).
59. Black DM, Sprecher DL: Dietary treatment and growth of hyperchylomicronemic children severely restricted in dietary fat. Am. J. Dis. Child 147(1), 60-62 (1993).
60. Santamarina-Fojo S: The familial chylomicronemia syndrome. Endocrinol. Metab. Clin. North Am. 27(3), 551-567, viii (1998).
61. Gagne C, Brun LD, Julien P, Moorjani S, Lupien PJ: Primary lipoprotein-lipase-activity deficiency: clinical investigation of a French Canadian population. CMAJ 140(4), 405-411 (1989).
62. Toskes PP: Hyperlipidemic pancreatitis. Gastroenterol. Clin. North Am. 19(4), 783-791 (1990).
63. Zhang X, Qi R, Xian X et al.: Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ. Res. 102(2), 250-256 (2008).
64. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M: Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N. Engl. J. Med. 335(12), 848-854 (1996).
65. Saika Y, Sakai N, Takahashi M et al.: Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis. Eur. J. Clin. Invest. 33(3), 216-222 (2003).
66. Ebara T, Ramakrishnan R, Steiner G, Shachter NS: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99(11), 2672-2681 (1997).
67. Wang J, Hegele RA: Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis. 6, 23 (2007).
68. Kathiresan S, Melander O, Guiducci C et al.: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40(2), 189-197 (2008).
69. Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176(8), 1113-1120 (2007).
70. Brunzell JD: Clinical practice. Hypertriglyceridemia. N. Engl. J. Med. 357(10), 1009-1017 (2007).
71. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19), 2088-2093 (1998).
72. Durrington P: Dyslipidaemia. Lancet 362(9385), 717-731 (2003).
73. Grundy SM, Mok HY, Zech L, Berman M: Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22(1), 24-36 (1981).
74. Jin FY, Kamanna VS, Kashyap ML: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. 19(4), 1051-1059 (1999):
75. Paolini JE, Mitchel YB, Reyes R et al.: Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol. 101(5), 625-630 (2008).
76. Vega GL, Grundy SM: Effect of starins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am. J. Cardiol. 81(4A), 36B-42B (1998).
77. Deedwania P, Barter P, Carmena. R et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of die Treating to New Targets study. Lancet 368(9539), 919-928 (2006).
78. Diabetes Atorvastin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24(8), 1335-1341 (2001).
79. Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004).
80. Rosenson RS: Effects of peroxisome proliferaror-activated receptors on lipoprotein metabolism and glucose control in Type 2 diabetes mellirus. Am. J. Cardiol. 99(4A), 96B-104B (2007).
81. Goldberg RB, Kendall DM, Deeg MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28(7), 1547-1554 (2005).
82. Bays HE, Tighe AP, Sadovsky R, Davidson MH: Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3), 391-409 (2008).
83. Goldberg RB, Sabharwal AK: Fish oil in the treatment of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes. 15(2), 167-174 (2008).
84. Harris WS, Ginsberg HN, Arunakul N et al.: Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovarc. Risk 4(5-6), 385-391 (1997).
85. McKenney JM, Sica D: Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27(5), 715-728 (2007).
86. Park Y, Harris WS: Ornega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res. 44(3), 455-463 (2003).
87. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ: The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 153(1), 129-138 (2000).
88. Pownall HJ, Branchi D, Kilinc C et al.: Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143(2), 285-297 (1999).
89. Greenberger NJ, Rodgers JB, Isselbacher KJ: Absorption of medium and long chain triglycerides: factors influencing their hydrolysis and transport. J. Clin. Invest. 45(2), 217-227 (1966).
90. Rouis M, Dugi KA, Previato L et al.: Therapeutic response to medium-chain triglycerides and ∞-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arierioscler. Thromb. Vasc. Biol. 17(7), 1400-1406 (1997).
91. Tsutsumi K, Inoue Y, Shima A, Murase T: Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44(4), 411-417 (1995).
92. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92(1), 411-417 (1993).
93. Chiba T, Miura S, Sawamura F et al.: Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler. Thromb. Vasc. Biol. 17(11), 2601-2608 (1997).
94. Nierman MC, Rip J, Twisk J et al.: Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. Neth. J. Med. 63(1), 14-19 (2005).
95. Kay MA, Manno CS, Ragni MV et al.: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24(3), 257-261 (2000).
96. Ross CJ, Twisk J, Meulenberg JM et al.: Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum. Gene Ther. 15(9), 906-919 (2004).
97. Ross CJ, Liu G, Kuivenhoven JA et al.: Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler. Thromb. Vasc. Biol. 25(10), 2143-2150 (2005).
98. Crooke RM: Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin. Biol. Ther. 5(7), 907-917 (2005).
99. Akdim.F, El Harchaoui K, Stroes ES, Kastelein JJ: Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidol. 2(4), 387-393 (2007).
100. Subramaniam A, Lemonidis KM, Graham MJ, Whipple CP, Crooke RM: ApoC-III antisense oligonucleotides reduce liver mRNA and serum triglyceride levels in hypertriglyceridemic rats. Presented at: American Diabetes Association. Annual Meeting. San Diego, CA, USA June 10-15 2005.
101. Priore Oliva C, Pisciotta L, Li VG et al.: Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25(2), 411-417 (2005).
102. Marcais C, Verges B, Charriere S et al.: Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronernia due to lipoprotein lipase impairment. J. Clin. Invest. 115(10), 2862-2869 (2005).
103. Calandra S, Priore Oliva C, Tarugi P, Bertolini S: APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr. Opin. Lipidol. 17(2), 122-127 (2006).
104. Prioie Oliva C, Carubbi F, Schaap FG, Bertolini S, Calandra S: Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J. Intern. Med. 263(4), 450-458 (2008).
105. Connelly PW, Maguire G.F. Little JA: Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. J. Clin. Invest. 80(6), 1597-1606 (1987).
106. Hegele RA, Connelly PW, Maguire GF et al.: An apolipoprotein CII mutation, CIILys19-Thr identified in patients with hyperlipidemia. Dis. Markers 9(2), 73-80 (1991).
107. Tuzgol S, Bijvoet SM, Bruin T, Kastelein JJ, Hayden MR: Apolipoprorein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana. J. Med. Genet. 31(8), 622-626 (1994).
108. de Graaf J, Hoffer MJ, Stuyt PM, Frants RR, Stalenhoef AF: Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCIIgene and the first APOCIV gene mutation: APOCII-CIV (Nijmegen). Biochem. Biopbys. Res. Commun. 273(3), 1084-1087 (2000).